DDInter379 DDInter1658
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Cilostazol {u} (Compound) binds {v} (Gene) PDE3A
Cilostazol {u} (Compound) upregulates {v} (Gene) RRP8
Cilostazol {u} (Compound) palliates {v} (Disease) systemic scleroderma
Cilostazol {u} (Compound) downregulates {v} (Gene) PPP2R5E
Cilostazol {u} (Compound) causes {v} (Side Effect) Arthritis
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brivaracetam
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Adenosine
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Cilostazol {u} may lead to a major life threatening interaction when taken with {v} Fondaparinux
Cilostazol (Compound) binds PDE3A (Gene)
Cilostazol (Compound) upregulates RRP8 (Gene)
Cilostazol (Compound) palliates systemic scleroderma (Disease)
Cilostazol (Compound) downregulates PPP2R5E (Gene)
Cilostazol (Compound) causes Arthritis (Side Effect)
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Adenosine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Cilostazol may lead to a major life threatening interaction when taken with Fondaparinux